摘要
目的探讨微阵列酶联免疫法(Array-ELISA)检测多项肿瘤标志物诊断结直肠癌(CRC)的临床价值。方法选择CRC患者49例(CRC组)、结直肠良性疾病患者19例(良性疾病组)、健康体检者71例(对照组),采用Array-ELISA法检测其血清甲胎蛋白(AFP)、癌胚抗原(CEA)、前列腺特异性抗体(PSA)、CA125、CA199、CA153。应用Logistic回归和受试者工作曲线对各指标进行相关性分析。结果 CRC组CA199、CA125、CEA均高于对照组及良性疾病组,良性疾病组CEA高于对照组(P均<0.05);三组CA153、PSA、AFP比较无统计学差异。CA125、CA199、CA153联合检测诊断CRC的敏感性为73.47%、准确度为85.61%、阴性预测值为86.46%,与其单项指标比较均有统计学差异(P均<0.05),其特异性、阳性预测值比较无统计学差异。CA125、CA199、CA153联合检测的曲线下面积大于其单项指标(P<0.05)。结论 CA199、CA125、CEA是CRC的肿瘤相关性标志物,采用Array-ELI技术联合检测三项指标诊断CRC的敏感性、准确度优于其单项指标。
Objective To investigate the clinic application value of Array-ELISA in diagnosing colorectal carcinoma by detecting multi-tumor markers.Method Using Array-ELISA to determine and analyze the concentration values of 6 tumor markers（AFP,CEA,PSA,CA125,CA199 and CA153） in sera of 49 colorectal carcinoma（CRC group）,19 patients with benign colorectal disorders（benign disease group）,and 71 normal individuals（control group）.The results were analyzed by logistic regression equation and ROC curve.Results The serum levels of CA199,CA125,CEA in CRC group were higher than those of control group and benign disease group（P0.05）.The levels of the other three tumor markers including CA153,PSA and AFP were not significantly different among the three groups（P0.05）.The sensitivity,accuracy and negative predictive rate of combined three tumor markers of serum CA199,CA125 and CEA to diagnose CRC were 73.47%,85.61% and 86.46%,Which had prognostic significance compared to CA199,CA125 and CEA alone（P0.05）.There was no statistical significance in specificity and negative predictive rate betweer three tumor markers and single tumor markers.The AUC of three combined tumor markers of CA199,CA125 and CEA was higher than any AUC of CA199,CA125 or CEA alone（P0.05）.Conclusions CA199,CA125 and CEA were the correlative tumor markers of colorectal carcinoma.With Array-ELISA technology,detection of combining CA199,CA125 and CEA was better than single tumor marker,which can raise the sensitivity and accuracy of diagnosing patients with colorectal carcinoma.
出处
《山东医药》
CAS
北大核心
2011年第45期13-15,共3页
Shandong Medical Journal
基金
江苏省卫生厅科技项目(H200919)
